215 related articles for article (PubMed ID: 19118707)
1. Cost-effectiveness.
Tuulonen A; Azuara-Blanco A
Ophthalmology; 2009 Jan; 116(1):166-7; author reply 167. PubMed ID: 19118707
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness.
Brown GC; Brown MM
Ophthalmology; 2008 Aug; 115(8):1433; author reply 1433-4. PubMed ID: 18675701
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness.
Lichter PR
Ophthalmology; 2008 Oct; 115(10):1852-3; author reply 1853. PubMed ID: 18929170
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of treating ocular hypertension.
Stewart WC; Stewart JA; Nasser QJ; Mychaskiw MA
Ophthalmology; 2008 Jan; 115(1):94-8. PubMed ID: 18166406
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
Rosenbaum LJ
Am J Ophthalmol; 2007 Jan; 143(1):191-2; author reply 192-3. PubMed ID: 17188074
[No Abstract] [Full Text] [Related]
6. Clinical outcomes of glaucoma treatment over a patient lifetime: a Markov model (letter).
Kymes S
J Glaucoma; 2006 Oct; 15(5):471-2; author reply 472-3. PubMed ID: 16988613
[No Abstract] [Full Text] [Related]
7. Glaucoma: where to now?
Taylor HR
Ophthalmology; 2009 May; 116(5):821-2. PubMed ID: 19410940
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of treating normal tension glaucoma.
Li EY; Tham CC; Chi SC; Lam DS
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3394-9. PubMed ID: 23599342
[TBL] [Abstract][Full Text] [Related]
9. Glaucoma care cost-effectiveness.
Hoskins HD
Ophthalmology; 2009 May; 116(5):1016. PubMed ID: 19410965
[No Abstract] [Full Text] [Related]
10. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
11. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
[TBL] [Abstract][Full Text] [Related]
13. The increased cost of medical services for people diagnosed with primary open-angle glaucoma: a decision analytic approach.
Kymes SM; Plotzke MR; Li JZ; Nichol MB; Wu J; Fain J
Am J Ophthalmol; 2010 Jul; 150(1):74-81. PubMed ID: 20493465
[TBL] [Abstract][Full Text] [Related]
14. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study.
Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO;
Am J Ophthalmol; 2006 Jun; 141(6):997-1008. PubMed ID: 16765666
[TBL] [Abstract][Full Text] [Related]
15. An introduction to decision analysis in the economic evaluation of the prevention and treatment of vision-related diseases.
Kymes SM
Ophthalmic Epidemiol; 2008; 15(2):76-83. PubMed ID: 18432490
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model.
Stewart WC; Stewart JA; Mychaskiw MA
Eye (Lond); 2009 Jan; 23(1):132-40. PubMed ID: 17721497
[TBL] [Abstract][Full Text] [Related]
17. Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.
Kymes SM; Plotzke MR; Kass MA; Boland MV; Gordon MO
Arch Ophthalmol; 2010 May; 128(5):613-8. PubMed ID: 20457984
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
19. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation.
Burr JM; Botello-Pinzon P; Takwoingi Y; Hernández R; Vazquez-Montes M; Elders A; Asaoka R; Banister K; van der Schoot J; Fraser C; King A; Lemij H; Sanders R; Vernon S; Tuulonen A; Kotecha A; Glasziou P; Garway-Heath D; Crabb D; Vale L; Azuara-Blanco A; Perera R; Ryan M; Deeks J; Cook J
Health Technol Assess; 2012 Jun; 16(29):1-271, iii-iv. PubMed ID: 22687263
[TBL] [Abstract][Full Text] [Related]
20. Is more always better?
Tuulonen A
Acta Ophthalmol Scand; 2004 Aug; 82(4):377-9. PubMed ID: 15291927
[No Abstract] [Full Text] [Related]
[Next] [New Search]
